Alcaftadine

DB06766ApprovedSmall moleculeHistamine H1 Antagonists

Alcaftadine is a H1 histamine receptor antagonist for ophthalmic use to prevent itching associated with allergic conjunctivitis. This drug was approved in July 2010.

Mechanism: Alcaftadine is a H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
Curator reviewed
Primary indication: For the prevention of itching associated with allergic conjunctivitis.Curator reviewed · 1 structured indication
Formula / weight: C₁₉H₂₁N₃O · 307.3895 g/mol (avg)
First approval: United States, 2010
Code names: R-89674
Brand names: Lastacaft

Resolves to

Compound

UNII7Z8O94ECSXCAS147084-10-4ChEMBLCHEMBL1201747ChEBI71023PubChem19371515KEGGD06552

Clinical / RWD

RxNorm1000082ATCS01GX11PharmGKBPA165958399

Structure

InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-NSMILESCN1CCC(CC1)=C1C2=NC=C(C=O)N2CCC2=CC=CC=C12

Targets

P35367HRH1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

384Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

16Marketed productsAcross 6 countries and 11 labellers

1ATC codeIncluding every combination product, plus 11 drug categories

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alcaftadine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In